Since its inception in 2009, Kodiak Sciences has developed a proprietary Antibody Biopolymer Conjugate (ABC) platform enabling extended durability in retinal therapies. Its lead candidate, tarcocimab tedromer (Zenkuda), has reported strong Phase 3 results in diabetic retinopathy and related retinal diseases. While the company continues pivotal studies, including the ongoing DAYBREAK trial, it faces substantial operating losses and clinical development risks. Kodiak maintains significant cash reserves and operational control over manufacturing, positioning it for potential near-term commercialization pending regulatory milestones.